Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy.
Compassionate use programme
Hereditary transthyretin amyloidosis
Patisiran
Real-world
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
16 Apr 2024
16 Apr 2024
Historique:
received:
27
10
2023
accepted:
23
03
2024
medline:
16
4
2024
pubmed:
16
4
2024
entrez:
15
4
2024
Statut:
aheadofprint
Résumé
Hereditary transthyretin (ATTRv, v for variant) amyloidosis with polyneuropathy is a rare disease caused by mutations in the transthyretin gene. In ATTRv amyloidosis, multisystem extracellular deposits of amyloid cause tissue and organ dysfunction. Patisiran is a small interfering RNA molecule drug that reduces circulating levels of mutant and wild-type TTR proteins. Prior to its regulatory approval, patisiran was available in Italy through a compassionate use programme (CUP). The aim of this study was to analyse the long-term outcomes of patients who entered into the CUP. This was a multicentre, observational, retrospective study of patients with ATTRv amyloidosis treated with patisiran. The analysis included change from baseline to 12, 24, 36 and 48 months in familial amyloid polyneuropathy (FAP) stage, polyneuropathy disability (PND) class, neuropathy impairment score (NIS), modified body mass index (mBMI), Compound Autonomic Dysfunction Test (CADT), Karnofsky Performance Status (KPS) scale and Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) questionnaire. Safety data were also analysed. Forty patients from 11 Italian centres were enrolled: 23 in FAP 1 (6 in PND 1 and 17 in PND 2) and 17 in FAP 2 (8 in PND 3a and 9 in PND 3b) stage. In this population, the mean NIS at baseline was 71.4 (± 27.8); mBMI, 917.1 (± 207) kg/m Patisiran largely stabilised disease in patients with ATTRv amyloidosis.
Sections du résumé
BACKGROUND
BACKGROUND
Hereditary transthyretin (ATTRv, v for variant) amyloidosis with polyneuropathy is a rare disease caused by mutations in the transthyretin gene. In ATTRv amyloidosis, multisystem extracellular deposits of amyloid cause tissue and organ dysfunction. Patisiran is a small interfering RNA molecule drug that reduces circulating levels of mutant and wild-type TTR proteins. Prior to its regulatory approval, patisiran was available in Italy through a compassionate use programme (CUP). The aim of this study was to analyse the long-term outcomes of patients who entered into the CUP.
METHODS
METHODS
This was a multicentre, observational, retrospective study of patients with ATTRv amyloidosis treated with patisiran. The analysis included change from baseline to 12, 24, 36 and 48 months in familial amyloid polyneuropathy (FAP) stage, polyneuropathy disability (PND) class, neuropathy impairment score (NIS), modified body mass index (mBMI), Compound Autonomic Dysfunction Test (CADT), Karnofsky Performance Status (KPS) scale and Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) questionnaire. Safety data were also analysed.
RESULTS
RESULTS
Forty patients from 11 Italian centres were enrolled: 23 in FAP 1 (6 in PND 1 and 17 in PND 2) and 17 in FAP 2 (8 in PND 3a and 9 in PND 3b) stage. In this population, the mean NIS at baseline was 71.4 (± 27.8); mBMI, 917.1 (± 207) kg/m
CONCLUSIONS
CONCLUSIONS
Patisiran largely stabilised disease in patients with ATTRv amyloidosis.
Identifiants
pubmed: 38622453
doi: 10.1007/s10072-024-07494-9
pii: 10.1007/s10072-024-07494-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Fondazione Società Italiana di Neurologia.
Références
Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M (2020) Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Ther Clin Risk Manag 16:109–123. https://doi.org/10.2147/TCRM.S219979
doi: 10.2147/TCRM.S219979
pubmed: 32110029
pmcid: 7041433
Koike H, Katsuno M (2020) Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies. Neurol Ther 9(2):317–333. https://doi.org/10.1007/s40120-020-00210-7
doi: 10.1007/s40120-020-00210-7
pubmed: 32948978
pmcid: 7500251
Coelho T, Ines M, Conceicao I, Soares M, de Carvalho M, Costa J (2018) Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology 91(21):e1999–e2009. https://doi.org/10.1212/WNL.0000000000006543
doi: 10.1212/WNL.0000000000006543
pubmed: 30333157
Adams D, Coelho T, Obici L, Merlini G, Mincheva Z, Suanprasert N, Bettencourt BR, Gollob JA, Gandhi PJ, Litchy WJ, Dyck PJ (2015) Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. Neurology 85(8):675–682. https://doi.org/10.1212/WNL.0000000000001870
doi: 10.1212/WNL.0000000000001870
pubmed: 26208957
pmcid: 4553033
Benson MD, Kincaid JC (2007) The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36(4):411–423. https://doi.org/10.1002/mus.20821
doi: 10.1002/mus.20821
pubmed: 17554795
Manganelli F, Fabrizi GM, Luigetti M, Mandich P, Mazzeo A, Pareyson D (2022) Hereditary transthyretin amyloidosis overview. Neurol Sci 43(Suppl 2):595–604. https://doi.org/10.1007/s10072-020-04889-2
doi: 10.1007/s10072-020-04889-2
pubmed: 33188616
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS (2019) Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73(22):2872–2891. https://doi.org/10.1016/j.jacc.2019.04.003
doi: 10.1016/j.jacc.2019.04.003
pubmed: 31171094
pmcid: 6724183
Sousa MM, Cardoso I, Fernandes R, Guimaraes A, Saraiva MJ (2001) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 159(6):1993–2000. https://doi.org/10.1016/s0002-9440(10)63050-7
doi: 10.1016/s0002-9440(10)63050-7
pubmed: 11733349
Gonzalez-Duarte A (2019) Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis). Clin Auton Res 29(2):245–251. https://doi.org/10.1007/s10286-018-0514-2
doi: 10.1007/s10286-018-0514-2
pubmed: 29511897
Ferraro PM, D'Ambrosio V, Di Paolantonio A, Guglielmino V, Calabresi P, Sabatelli M, Luigetti M (2021) Renal involvement in hereditary transthyretin amyloidosis: an Italian single-centre experience. Brain Sci 11(8). https://doi.org/10.3390/brainsci11080980
Luigetti M, Romozzi M, Bisogni G, Cardellini D, Cavallaro T, Di Paolantonio A, Fabrizi GM, Fenu S, Gentile L, Grandis M, Marucci G, Massucco S, Mazzeo A, Pareyson D, Romano A, Russo M, Schenone A, Tagliapietra M, Tozza S, Vita G, Sabatelli M (2020) hATTR pathology: nerve biopsy results from Italian referral centers. Brain Sci 10(11):780. https://doi.org/10.3390/brainsci10110780
doi: 10.3390/brainsci10110780
pubmed: 33114611
pmcid: 7692609
Luigetti M, Tortora A, Romano A, Di Paolantonio A, Guglielmino V, Bisogni G, Gasbarrini A, Calabresi P, Sabatelli M (2020) Gastrointestinal manifestations in hereditary transthyretin amyloidosis: a single-centre experience. J Gastrointestin Liver Dis 29(3):339–43. https://doi.org/10.15403/jgld-2474
doi: 10.15403/jgld-2474
pubmed: 32919418
Plante-Bordeneuve V, Said G (2011) Familial amyloid polyneuropathy. Lancet Neurol 10(12):1086–1097. https://doi.org/10.1016/S1474-4422(11)70246-0
doi: 10.1016/S1474-4422(11)70246-0
pubmed: 22094129
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C, Investigators A-AS (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379(11):1007–16. https://doi.org/10.1056/NEJMoa1805689
doi: 10.1056/NEJMoa1805689
pubmed: 30145929
Cantone A, Sanguettoli F, Dal Passo B, Serenelli M, Rapezzi C (2022) The treatment of amyloidosis is being refined. Eur Heart J Suppl 24(Suppl I):I131–I138. https://doi.org/10.1093/eurheartjsupp/suac104
doi: 10.1093/eurheartjsupp/suac104
pubmed: 36380794
pmcid: 9653129
Padda IS, Mahtani AU, Parmar M (2023) Small Interfering RNA (siRNA) Based therapy. StatPearls [Internet]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing
Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plante-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11–21. https://doi.org/10.1056/NEJMoa1716153
doi: 10.1056/NEJMoa1716153
pubmed: 29972753
Adams D, Polydefkis M, Gonzalez-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada Lopez IA, Dispenzieri A, Quan D, Conceicao IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Plante-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T, patisiran Global OLEsg (2021) Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol 20(1):49–59. https://doi.org/10.1016/S1474-4422(20)30368-9
doi: 10.1016/S1474-4422(20)30368-9
pubmed: 33212063
Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J, Bettencourt BR, Geissler M, Butler JS, Sehgal A, Meyers RE, Chen Q, Borland T, Hutabarat RM, Clausen VA, Alvarez R, Fitzgerald K, Gamba-Vitalo C, Nochur SV, Vaishnaw AK, Sah DW, Gollob JA, Suhr OB (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369(9):819–829. https://doi.org/10.1056/NEJMoa1208760
doi: 10.1056/NEJMoa1208760
pubmed: 23984729
Di Stefano V, Fava A, Gentile L, Guaraldi P, Leonardi L, Poli L, Tagliapietra M, Vastola M, Fanara S, Ferrero B, Giorgi M, Perfetto F, Russo M, Russo D (2022) Italian real-life experience of patients with hereditary transthyretin amyloidosis treated with patisiran. Pharmgenomics Pers Med 15:499–514. https://doi.org/10.2147/PGPM.S359851
doi: 10.2147/PGPM.S359851
pubmed: 35592550
pmcid: 9113125
Suhr OB, Coelho T, Buades J, Pouget J, Conceicao I, Berk J, Schmidt H, Waddington-Cruz M, Campistol JM, Bettencourt BR, Vaishnaw A, Gollob J, Adams D (2015) Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis 10:109. https://doi.org/10.1186/s13023-015-0326-6
doi: 10.1186/s13023-015-0326-6
pubmed: 26338094
pmcid: 4559363
Luigetti M, Wixner J, Ueda M, Marquez W Jr, Dalia S, Arum S, Hale C, Jay P, Capocelli K, Adams D (2023) Patisiran global open-label extension study at 36 months: effect of long-term treatment on mortality and ambulatory function in patients with hATTR amyloidosis with polyneuropathy. J Peripher Nerv Syst 28(Suppl 2):S35. https://doi.org/10.1111/jns.12550
doi: 10.1111/jns.12550
Gentile L, Russo M, Luigetti M, Bisogni G, Di Paolantonio A, Romano A, Guglielmino V, Arimatea I, Sabatelli M, Toscano A, Vita G, Mazzeo A (2021) Patisiran in hATTR amyloidosis: six-month latency period before efficacy. Brain Sci 11(4):515. https://doi.org/10.3390/brainsci11040515
doi: 10.3390/brainsci11040515
pubmed: 33921571
pmcid: 8073153
Coutinho PM, Martins da Silva A, Lopes JL, Barbarosa AR (1980) Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner GG, Costa PP, de Freitas AF (eds) Amyloid amyloidosis. Excerpta Medica, Amsterdam. https://www.spmi.pt/wp-content/uploads/2019/10/9.-Amyloid-and-Amyloidosis-1979.pdf
Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksanen A, Iwata T, Gjertsen H, Soderdahl G, Wikstrom L, Ando Y, Suhr OB, Ericzon BG (2007) Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant 7(11):2597–2604. https://doi.org/10.1111/j.1600-6143.2007.01969.x
doi: 10.1111/j.1600-6143.2007.01969.x
pubmed: 17868062
Dyck PJ, Boes CJ, Mulder D, Millikan C, Windebank AJ, Dyck PJ, Espinosa R (2005) History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation. J Peripher Nerv Syst 10(2):158–73. https://doi.org/10.1111/j.1085-9489.2005.0010206.x
doi: 10.1111/j.1085-9489.2005.0010206.x
pubmed: 15958127
Denier C, Ducot B, Husson H, Lozeron P, Adams D, Meyer L, Said G, Plante-Bordeneuve V (2007) A brief compound test for assessment of autonomic and sensory-motor dysfunction in familial amyloid polyneuropathy. J Neurol 254(12):1684–1688. https://doi.org/10.1007/s00415-007-0617-5
doi: 10.1007/s00415-007-0617-5
pubmed: 18074076
Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, p 196
Vinik EJ, Hayes RP, Oglesby A, Bastyr E, Barlow P, Ford-Molvik SL, Vinik AI (2005) The development and validation of the Norfolk QOL-DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther 7(3):497–508. https://doi.org/10.1089/dia.2005.7.497
doi: 10.1089/dia.2005.7.497
pubmed: 15929681
ClinTrials.gov. The study of an investigational drug, patisiran (ALN-TTR02), for the treatment of transthyretin (TTR)-mediated amyloidosis in participants who have already been treated with ALN-TTR02 (patisiran) [Internet]. ClinicalTrials.gov. 2023. Available from: https://clinicaltrials.gov/study/NCT02510261?tab=results#outcome-measures . Accessed 26 Feb 2024
de Frutos F, Ochoa JP, Gomez-Gonzalez C, Reyes-Leiva D, Arostegui JI, Casasnovas C, Barriales-Villa R, Sevilla T, Gonzalez-Lopez E, Ramil E, Galan L, Gonzalez-Costello J, Garcia-Alvarez A, Rojas-Garcia R, Espinosa MA, Garcia-Pavia P (2023) Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain. Amyloid 30(2):199–207. https://doi.org/10.1080/13506129.2022.2142110
doi: 10.1080/13506129.2022.2142110
pubmed: 36343383
Labeyrie C, Merkel M, Sethi S, Popadic L, Yang H, Lin H, Adams D (2022) Effectiveness of patisiran following switch from tafamidis for the treatment of heredirary transthyretin-mediatied (hATTR) amyloidosis with polyneuropathy. XVIII International Symposium on Amyloidosis, 4th–8th September 2022, Heidelberg, Germany
Quan D, Obici L, Berk JL, Ando Y, Aldinc E, White MT, Adams D (2023) Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial. Amyloid 30(1):49–58. https://doi.org/10.1080/13506129.2022.2118043
doi: 10.1080/13506129.2022.2118043
pubmed: 36120830
De Bleecker JL, Claeys KG, Delstanche S, Van Parys V, Baets J, Tilleux S, Remiche G (2023) A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium. Acta Neurol Belg 123(3):1029–1037. https://doi.org/10.1007/s13760-023-02188-z
doi: 10.1007/s13760-023-02188-z
pubmed: 36829087
pmcid: 10238330
Schmidt HH, Wixner J, Plante-Bordeneuve V, Munoz-Beamud F, Llado L, Gillmore JD, Mazzeo A, Li X, Arum S, Jay PY, Adams D, Patisiran Post LTSG (2022) Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation. Am J Transplant 22(6):1646–57. https://doi.org/10.1111/ajt.17009
doi: 10.1111/ajt.17009
pubmed: 35213769
pmcid: 9310767
Yarlas A, Gertz MA, Dasgupta NR, Obici L, Pollock M, Ackermann EJ, Lovley A, Kessler AS, Patel PA, White MK, Guthrie SD (2019) Burden of hereditary transthyretin amyloidosis on quality of life. Muscle Nerve 60(2):169–175. https://doi.org/10.1002/mus.26515
doi: 10.1002/mus.26515
pubmed: 31093980
pmcid: 6771567
Brannagan TH 3rd, Auer-Grumbach M, Berk JL, Briani C, Bril V, Coelho T, Damy T, Dispenzieri A, Drachman BM, Fine N, Gaggin HK, Gertz M, Gillmore JD, Gonzalez E, Hanna M, Hurwitz DR, Khella SL, Maurer MS, Nativi-Nicolau J, Olugemo K, Quintana LF, Rosen AM, Schmidt HH, Shehata J, Waddington-Cruz M, Whelan C, Ruberg FL (2021) ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. Orphanet J Rare Dis 16(1):204. https://doi.org/10.1186/s13023-021-01834-0
doi: 10.1186/s13023-021-01834-0
pubmed: 33957949
pmcid: 8100737
Gonzalez-Duarte A, Berk JL, Quan D, Mauermann ML, Schmidt HH, Polydefkis M, Waddington-Cruz M, Ueda M, Conceicao IM, Kristen AV, Coelho T, Cauquil CA, Tard C, Merkel M, Aldinc E, Chen J, Sweetser MT, Wang JJ, Adams D (2020) Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. J Neurol 267(3):703–712. https://doi.org/10.1007/s00415-019-09602-8
doi: 10.1007/s00415-019-09602-8
pubmed: 31728713
EMA. ONPATTRO, INN-patisiran. Summary of Product Characteristics (2018) [Available from: https://www.ema.europa.eu/en/documents/product-information/onpattro-epar-product-information_en.pdf .] Accessed 20 Jun 2023